Here's Why We're Not Too Worried About Bougainville Copper's (ASX:BOC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.
So should Bougainville Copper (ASX:BOC) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Bougainville Copper last reported its December 2024 balance sheet in February 2025, it had zero debt and cash worth K21m. In the last year, its cash burn was K14m. Therefore, from December 2024 it had roughly 19 months of cash runway. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. The image below shows how its cash balance has been changing over the last few years.
See our latest analysis for Bougainville Copper
Whilst it's great to see that Bougainville Copper has already begun generating revenue from operations, last year it only produced K3.4m, so we don't think it is generating significant revenue, at this point. As a result, we think it's a bit early to focus on the revenue growth, so we'll limit ourselves to looking at how the cash burn is changing over time. Over the last year its cash burn actually increased by a very significant 72%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Of course, we've only taken a quick look at the stock's growth metrics, here. You can take a look at how Bougainville Copper has developed its business over time by checking this visualization of its revenue and earnings history .
While Bougainville Copper does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.
Since it has a market capitalisation of K328m, Bougainville Copper's K14m in cash burn equates to about 4.2% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.
Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Bougainville Copper's cash burn relative to its market cap was relatively promising. While we're the kind of investors who are always a bit concerned about the risks involved with cash burning companies, the metrics we have discussed in this article leave us relatively comfortable about Bougainville Copper's situation. On another note, Bougainville Copper has 3 warning signs (and 2 which shouldn't be ignored) we think you should know about.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts)
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
20 hours ago
- Business Upturn
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026 SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected]. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
21 hours ago
- Yahoo
Are Accent Group Limited's (ASX:AX1) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
With its stock down 27% over the past month, it is easy to disregard Accent Group (ASX:AX1). It is possible that the markets have ignored the company's differing financials and decided to lean-in to the negative sentiment. Stock prices are usually driven by a company's financial performance over the long term, and therefore we decided to pay more attention to the company's financial performance. Particularly, we will be paying attention to Accent Group's ROE today. Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The formula for ROE is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Accent Group is: 14% = AU$64m ÷ AU$446m (Based on the trailing twelve months to December 2024). The 'return' is the profit over the last twelve months. That means that for every A$1 worth of shareholders' equity, the company generated A$0.14 in profit. See our latest analysis for Accent Group Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. To begin with, Accent Group seems to have a respectable ROE. And on comparing with the industry, we found that the the average industry ROE is similar at 15%. Despite the modest returns, Accent Group's five year net income growth was quite low, averaging at only 3.4%. So, there could be some other factors at play that could be impacting the company's growth. For instance, the company pays out a huge portion of its earnings as dividends, or is faced with competitive pressures. We then compared Accent Group's net income growth with the industry and found that the company's growth figure is lower than the average industry growth rate of 7.2% in the same 5-year period, which is a bit concerning. Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Accent Group fairly valued compared to other companies? These 3 valuation measures might help you decide. Accent Group has a very high three-year median payout ratio of 110%suggesting that the company's shareholders are getting paid from more than just the company's income. This is indicative of risk. To know the 2 risks we have identified for Accent Group visit our risks dashboard for free. Moreover, Accent Group has been paying dividends for at least ten years or more suggesting that management must have perceived that the shareholders prefer dividends over earnings growth. Upon studying the latest analysts' consensus data, we found that the company's future payout ratio is expected to drop to 71% over the next three years. Despite the lower expected payout ratio, the company's ROE is not expected to change by much. In total, we're a bit ambivalent about Accent Group's performance. In spite of the high ROE, the company has failed to see growth in its earnings due to it paying out most of its profits as dividend, with almost nothing left to invest into its own business. With that said, the latest industry analyst forecasts reveal that the company's earnings are expected to accelerate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Emerald Resources NL's (ASX:EMR) institutional investors lost 13% last week but have benefitted from longer-term gains
Significantly high institutional ownership implies Emerald Resources' stock price is sensitive to their trading actions A total of 10 investors have a majority stake in the company with 50% ownership Insider ownership in Emerald Resources is 18% Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in Emerald Resources NL (ASX:EMR) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 43% to be precise, is institutions. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Losing money on investments is something no shareholder enjoys, least of all institutional investors who saw their holdings value drop by 13% last week. Still, the 21% one-year gains may have helped mitigate their overall losses. They should, however, be mindful of further losses in the future. Let's take a closer look to see what the different types of shareholders can tell us about Emerald Resources. View our latest analysis for Emerald Resources Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. Emerald Resources already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Emerald Resources' earnings history below. Of course, the future is what really matters. Emerald Resources is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is BlackRock, Inc. with 8.0% of shares outstanding. With 7.9% and 6.0% of the shares outstanding respectively, Van Eck Associates Corporation and Morgan Hart are the second and third largest shareholders. Morgan Hart, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. We did some more digging and found that 10 of the top shareholders account for roughly 50% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is some analyst coverage of the stock, but it could still become more well known, with time. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that insiders maintain a significant holding in Emerald Resources NL. Insiders own AU$483m worth of shares in the AU$2.7b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently. With a 34% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Emerald Resources. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. It seems that Private Companies own 4.5%, of the Emerald Resources stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.2% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
